Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;160(1):79-100.
doi: 10.1007/s11060-022-04118-0. Epub 2022 Aug 23.

Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials

Paolo Palmisciano  1 , Gina Watanabe  2 , Andie Conching  2 , Christian Ogasawara  3 , Morana Vojnic  4 , Randy S D'Amico  5
Affiliations

Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials

Paolo Palmisciano et al. J Neurooncol. 2022 Oct.

Abstract

Purpose: Leptomeningeal metastatic disease (LMD) from advanced malignancies has poor prognoses and limited treatments. Intrathecal therapy (ITT) protocols are available, showing variable outcomes. We reviewed the therapeutic and toxicity profiles of ITT in LMD.

Methods: PubMed, EMBASE, Web-of-Science, and Scopus were searched following the PRISMA-ScR guidelines to include studies reporting ITT for LMD.

Clinicaltrial: gov and Cochrane were searched to identify ongoing clinical trials.

Results: We included 27 published studies encompassing 2161 patients and 4 ongoing trials. LMD originated from brain metastases (85.5%), lymphomas (5.4%), high-grade gliomas (4.6%), medulloblastomas (2.3%), and leukemias (2.1%). LMD was mostly diagnosed with the co-presence of neurological-related symptoms and positive imaging and/or cerebrospinal fluid cytology (60.8%). The most common ITT agents were methotrexate (35.9%), cytarabine (21.9%), and thiotepa (8.2%), standalone or combined. Patients received a median of 6.5 ITT cycles (range, 1.0-71.0) via intraventricular (58.8%) or lumbar intrathecal (41.2%) routes. The Ommaya reservoir was implanted in 38.5% cases. Concurrent systemic chemotherapy (45.2%) and/or radiotherapy (30.6%) were used. After 1-3 cycles, 44.7% patients had improved clinical status and 29.9% converted into negative cerebrospinal fluid cytology. The most common ITT-related severe adverse events were neutropenia (6.5%), meningitis (5.2%) and encephalopathy (4.5%). Median freedom from progression was 2.4 months (range, 0.1-59.5) and median overall survival 5.5 months (range, 0.1-148.0).

Conclusion: Current ITT protocols are variable but effective and well-tolerated in LMD. Ongoing trials are investigating dose-limiting toxicity profiles and long-term overall survival. Future studies should analyze the therapeutic and safety profiles of ITT compared to newer systemic therapies.

Keywords: Brain metastases; Chemotherapy; Intrathecal therapy; Leptomeningeal metastases; Ommaya reservoir.

PubMed Disclaimer

References

    1. Thakkar JP, Kumthekar P, Dixit KS et al (2020) Leptomeningeal metastasis from solid tumors. J Neurol Sci 411:116706. https://doi.org/10.1016/j.jns.2020.116706 - DOI - PubMed
    1. Freilich RJ, Krol G, Deangelis LM (1995) Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38:51–57. https://doi.org/10.1002/ana.410380111 - DOI - PubMed
    1. Sener U, Kumthekar P, Boire A (2021) Advances in the diagnosis, evaluation, and management of leptomeningeal disease. Neuro-Oncol Adv 3:v86–v95. https://doi.org/10.1093/noajnl/vdab108 - DOI
    1. Wang N, Bertalan MS, Brastianos PK (2018) Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer 124:21–35. https://doi.org/10.1002/cncr.30911 - DOI - PubMed
    1. Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 11:871–879. https://doi.org/10.1016/S1470-2045(10)70034-6 - DOI - PubMed

Publication types

LinkOut - more resources